Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Study of HEC88473 in Healthy Subjects
NCT04829123Phase 1Completed
- Start
- May 2021
- Primary completion
- Mar 2022
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of HEC88473 in Nonalcoholic steatohepatitis (NASH) (11 arms). Primary endpoints: Frequency and severity of Adverse Events (AEs) and Serious Adverse Events (SAEs) after a single dose, Frequency and severity of Adverse Events (AEs) and Serious Adverse Events (SAEs) after multiple doses and 2 more. Started May 2021; status: completed.
02
Drugs
HEC88473
03
Conditions
Nonalcoholic steatohepatitis (NASH)
Beyond the preview
Go deeper on NCT04829123.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04829123.